AAAAAA

   
Results: 1-17 |
Results: 17
Factors predictive of outcome in patients with breast cancer refractory toneoadjuvant chemotherapy
Authors: Buchholz, TA Hill, BS Tucker, SL Frye, DK Kuerer, HM Buzdar, AU McNeese, MD Singletary, SE Ueno, NT Pusztai, L Valero, V Hortobagyi, GN
Citation: Ta. Buchholz et al., Factors predictive of outcome in patients with breast cancer refractory toneoadjuvant chemotherapy, CANCER J, 7(5), 2001, pp. 413-420
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial
Authors: Hortobagyi, GN Ueno, NT Xia, WY Zhang, S Wolf, JK Putnam, JB Weiden, PL Willey, JS Carey, M Branham, DL Payne, JY Tucker, SD Bartholomeusz, C Kilbourn, RG De Jager, RL Sneige, N Katz, RL Anklesaria, P Ibrahim, NK Murray, JL Theriault, RL Valero, V Gershenson, DM Bevers, MW Huang, L Lopez-Berestein, G Hung, MC
Citation: Gn. Hortobagyi et al., Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial, J CL ONCOL, 19(14), 2001, pp. 3422-3433
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia
Authors: Bibawi, S Abi-Said, D Fayad, L Anderlini, P Ueno, NT Mehra, R Khouri, I Giralt, S Gajewski, J Donato, M Claxton, D Braunschweig, I van Besien, K Andreeff, M Andersson, BS Estey, EH Champlin, R Przepiorka, D
Citation: S. Bibawi et al., Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia, AM J HEMAT, 67(4), 2001, pp. 227-233
Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins
Authors: Ghosh, S Champlin, RE Ueno, NT Anderlini, P Rolston, K Raad, I Kontoyiannis, D Jacobson, K Luna, M Tarrand, J Whimbey, E
Citation: S. Ghosh et al., Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins, BONE MAR TR, 28(3), 2001, pp. 271-275
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
Authors: Shimoni, A Smith, TL Aleman, A Weber, D Dimopoulos, M Anderlini, P Andersson, B Claxton, D Ueno, NT Khouri, I Donato, M Korbling, M Alexanian, R Champlin, R Giralt, S
Citation: A. Shimoni et al., Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma, BONE MAR TR, 27(8), 2001, pp. 821-828
Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients
Authors: Konoplev, S Champlin, RE Giralt, S Ueno, NT Khouri, I Raad, I Rolston, K Jacobson, K Tarrand, J Luna, M Nguyen, Q Whimbey, E
Citation: S. Konoplev et al., Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients, BONE MAR TR, 27(8), 2001, pp. 877-881
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Authors: Giralt, S Thall, PF Khouri, I Wang, XM Braunschweig, I Ippolitti, C Claxton, D Donato, M Bruton, J Cohen, A Davis, M Andersson, BS Anderlini, P Gajewski, J Kornblau, S Andreeff, M Przepiorka, D Ueno, NT Molldrem, J Champlin, R
Citation: S. Giralt et al., Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation, BLOOD, 97(3), 2001, pp. 631-637
High-dose chemotherapy as treatment for high-risk primary and metastatic breast cancer
Authors: Ueno, NT Champlin, RE
Citation: Nt. Ueno et Re. Champlin, High-dose chemotherapy as treatment for high-risk primary and metastatic breast cancer, MDA CANC CA, 2001, pp. 342-365
Tacrolimus does not abrogate the increased risk of acute graft-versus-hostdisease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB I and HLA-DQB I
Authors: Przepiorka, D Saliba, R Cleary, K Fischer, H Tonai, R Fritsche, H Khouri, IF Folloder, J Ueno, NT Mehra, R Ippoliti, C Giralt, S Gajewski, J Donato, M Claxton, D Braunschweig, I van Besien, K Anderlini, P Andersson, BS Champlin, R
Citation: D. Przepiorka et al., Tacrolimus does not abrogate the increased risk of acute graft-versus-hostdisease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB I and HLA-DQB I, BIOL BLOOD, 6(2A), 2000, pp. 190-197
E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway
Authors: Ueno, NT Bartholomeusz, C Herrmann, JL Estrov, Z Shao, RP Andreeff, M Price, J Paul, RW Anklesaria, P Yu, DH Hung, MC
Citation: Nt. Ueno et al., E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway, CLIN CANC R, 6(1), 2000, pp. 250-259
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease
Authors: Anderlini, P Giralt, S Andersson, B Ueno, NT Khouri, I Acholonu, S Cohen, A Korbling, MJ Manning, J Romaguera, J Sarris, A Rodriguez, MA Hagemeister, F McLaughlin, P Cabanillas, F Champlin, RE
Citation: P. Anderlini et al., Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease, BONE MAR TR, 26(6), 2000, pp. 615-620
Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer
Authors: Hung, MC Hortobagyi, GN Ueno, NT
Citation: Mc. Hung et al., Development of clinical trial of E1A gene therapy targeting HER-2/neu-overexpressing breast and ovarian cancer, ADV EXP MED, 465, 2000, pp. 171-180
Issues in the development of gene therapy: Preclinical experiments in E1A gene delivery
Authors: Ueno, NT Xia, WY Tucker, SD Zhang, S Lopez-Berestein, G Huang, L Hung, MC
Citation: Nt. Ueno et al., Issues in the development of gene therapy: Preclinical experiments in E1A gene delivery, ONCOL REP, 6(2), 1999, pp. 257-262
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
Authors: Przepiorka, D van Besien, K Khouri, I Hagemeister, F Samuels, B Folloder, J Ueno, NT Molldrem, J Mehra, R Korbling, M Giralt, S Gajewski, J Donato, M Cleary, K Claxton, D Braunschweig, I Andersson, B Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma, ANN ONCOL, 10(5), 1999, pp. 527-532
Allogeneic hematopoietic transplantation as adoptive immunotherapy - Induction of graft-versus-malignancy as primary therapy
Authors: Champlin, R Khouri, I Kornblau, S Marini, F Anderlini, P Ueno, NT Molldrem, J Giralt, S
Citation: R. Champlin et al., Allogeneic hematopoietic transplantation as adoptive immunotherapy - Induction of graft-versus-malignancy as primary therapy, HEMAT ONCOL, 13(5), 1999, pp. 1041
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation
Authors: Przepiorka, D Khouri, I Ippoliti, C Ueno, NT Mehra, R Korbling, M Giralt, S Gajewski, J Fischer, H Donato, M Cleary, K Claxton, D Chan, KW Braunschweig, I van Besien, K Andersson, BS Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation, BONE MAR TR, 24(7), 1999, pp. 763-768
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation
Authors: Przepiorka, D Smith, TL Folloder, J Khouri, I Ueno, NT Mehra, R Korbling, M Huh, YO Giralt, S Gajewski, J Donato, M Cleary, K Claxton, D Braunschweig, I van Besien, K Andersson, BS Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation, BLOOD, 94(4), 1999, pp. 1465-1470
Risultati: 1-17 |